Stem Cell Assays Market by Type (Cell Proliferation & Cytotoxicity Assay, Cell Viability & Cycle Assay, Cell Apoptosis Assay, Cell Migration & Invasion Assay, Identification Assays & Function Assay, and Others), Cell Type (Adult Stem Cells, Human Embryonic Stem Cells, and Others), Detection [Instruments (Automated Counter, Flow Cytometers, Image Cytometers & Analysis Systems, and Others) and Detection Kits], Application [Regenerative Medicine & Therapy Development (Orthopedic & Musculoskeletal Spine, Cardiovascular, Oncology, Central Nervous System, Dermatology, Diabetes, and Others), Drug Discovery & Development, Clinical Research, and Others], End User (Pharmaceutical & Biopharmaceutical Companies, Academic & Research Institutes, and Others): Global Market Size Estimates and Forecast (2022-2030)

The market crossed US$ 1.12 billion mark in 2022 and is expected to hit US$ 5.89 billion by 2030, recording a CAGR of 23.1% during the forecast period.

Increasing funding for stem cell research has aided the stem cell assay market

In recent years, companies working on stem cell therapies have received venture capital investments. This has boosted the development of new therapies for diseases such as cancer. For instance, in March 2022, the City of Hope’s Irell & Manella Graduate School of Biological Sciences at Beckman Research Institute received a USD 4.9 million grant from the California Institute for Regenerative Medicine. The funding has significantly helped in training the scientific community in stem cell research and its translation into novel lifesaving treatments. The rise in approvals of clinical trials for stem cell-based therapy, rising prevalence of chronic diseases, increase in research-related activities in stem cells, and technological advancements in the area of stem cell assays method supplements the growth of the stem cell assay market. Adult stem cells accounted for the largest share of the stem cell assay market. Adult stem cells include mesenchymal stem cells, induced pluripotent stem cells, hematopoietic stem cells, umbilical cord stem cells, and neural stem cells. The growth of the segment is driven by the increasing usage of adult stem cells in regenerative medicine and in the development of advanced therapies.

Within the report, the market is segmented into type, cell type, detection, application, end user, and geography. By type, the market is further segmented into cell proliferation & cytotoxicity assay, cell viability & cycle assay, cell apoptosis assay, cell migration & invasion assay, identification assays & function assay, and others. On the basis of cell type, the market is segmented into adult stem cells, human embryonic stem cells, and others. By detection, the market is categorized into instruments (automated counter, flow cytometers, image cytometers & analysis systems, and others) and detection kits. By application, the market is categorized into regenerative medicine & therapy development (orthopedic & musculoskeletal spine, cardiovascular, oncology, central nervous system, dermatology, diabetes, and others), drug discovery & development, clinical research, and others. Based on end user, the market is segmented into pharmaceutical & biopharmaceutical companies, academic & research institutes, and others. Geographically, the market is subsegmented into North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

Technological advancements in stem cell assay areas

The development of label free assay technology wherein cells do not have to be genetically engineered for the assay is one of the recent advancements made in stem cell assay market. The cells can be cultured and assayed with no errors & manipulations and the results can be very insightful in nature. As a result, without any labels, cell modifications behave naturally.  This is a huge help for understanding the molecular pharmacology of the receptor in the normal environment. Label-free technology uses impedance- or optics-based biosensors to measure the changes that occur upon analyte binding to a ligand immobilized on a biosensor surface. The concerned methods are also desirable and compatible with real-time detection. Some broad spectrum of assays that can be determined using label free assay technology are molecular and cellular biology, cell growth/proliferation, toxicity screening, and GPCR functional selectivity, amongst others.

Regenerative medicine segment held the largest share in 2022

Regenerative medicine held the largest market share in 2022, owing to increasing approval for stem cell therapies and clinical trials targeting different diseases. For instance, in June 2020, Longeveron LLC announced Japan’s Pharmaceutical and Medical Devices Agency (PMDA) approval for the starting Phase 2 clinical trial to evaluate the safety and efficacy of their mesenchymal stem cells (LMSCs) that can be used for treating aging frailty. Besides, several governments are investing heavily in the development of regenerative medicines. For instance, in March 2020, the Government of Canada invested around US$ 6.9 million in regenerative medicine research. The funds will support 4 clinical trials and 9 translational projects aimed at bringing new therapies into the regenerative medicine sector.

Get more information on this report : Request Free Sample PDF

Recent strategic developments in stem cell assays market

The stem cell assays market has undergone several significant developments, and a few of these have been mentioned below:

• In January 2022, Agilent Technologies Inc. launched Seahorse XF Pro Analyzer, enabling operators to understand cellular fate, fitness, and function.
• In April 2020, Bio-Rad Laboratories acquired Celsee, Inc. With this acquisition, the company aims to expand its presence in the single-cell analysis market.

The stem cell assays market is driven by several players by implementing strategic activities such as investments, new launches, mergers & acquisitions, and partnerships. GE Healthcare, Thermo Fisher Scientific Inc., Merck KGaA, Cell Biolabs, Inc., Hemogenix Inc., STEMCELL Technologies Inc., Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Cellular Dynamics International, Inc., Promega Corporation, and Creative Bioarray are among the prominent players operating in the market.

Target audience for the report:

• Government bodies, such as regulating authorities and policy makers
• Healthcare Institutes
• Life Science Companies
• Stem Cell Companies
• Universities
• Pharmaceutical and Biopharmaceutical Companies
• Research institutes, organizations, and consulting companies

Scope of the report:

In this report, the market has been segmented on the basis of:

• Type:
  • Cell Proliferation and Cytotoxicity Assay
  • Cell Viability and Cycle Assay
  • Cell Apoptosis Assay
  • Cell Migration and Invasion Assay
  • Identification Assays and Function Assay
  • Others

• Cell Type
  • Adult Stem Cells
  • Human Embryonic Stem Cells (HESCs)
  • Others
• Detection:
  • Instruments
    • Automated Counter
    • Flow Cytometers
    • Image Cytometers and Analysis Systems
    • Others
  • Detection Kits
• Application:
  • Regenerative Medicine and Therapy Development
    • Orthopedic & Musculoskeletal Spine
    • Cardiovascular
    • Oncology
    • Central Nervous System
    • Dermatology
    • Diabetes
    • Others
  • Drug Discovery & Development
  • Clinical Research
  • Others
• End User
  • Pharmaceutical and Biopharmaceutical Companies
  • Academic and Research Institutes
  • Others
• Region
  • North America
  • Europe
  • Asia Pacific (APAC)
  • South & Central America
  • The Middle East & Africa
• Companies profiled
  • GE Healthcare
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Cell Biolabs, Inc.
  • Hemogenix Inc.
  • STEMCELL Technologies Inc.
  • Bio-Rad Laboratories, Inc
  • Bio-Techne Corporation
  • Cellular Dynamics International, Inc.
  • Promega Corporation
  • Creative Bioarray
  • Other Market Participants